ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OCGN Ocugen Inc

1.27
0.03 (2.42%)
Apr 23 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 6,900,697
Bid Price 1.25
Ask Price 1.27
News -
Day High 1.31

Low
0.345

52 Week Range

High
2.105

Day Low 1.18
Company Name Stock Ticker Symbol Market Type
Ocugen Inc OCGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 2.42% 1.27 19:58:42
Open Price Low Price High Price Close Price Prev Close
1.21 1.18 1.31 1.25 1.24
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
22,943 6,900,697 $ 1.25 $ 8,621,183 - 0.345 - 2.105
Last Trade Time Type Quantity Stock Price Currency
19:58:42 formt 1,978 $ 1.27 USD

Ocugen (OCGN) Options Flow Summary

Overall Flow

Bearish

Net Premium

-73k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

Ocugen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
318.06M 256.50M - 0 -81.35M -0.32 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Ocugen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No OCGN Message Board. Create One! See More Posts on OCGN Message Board See More Message Board Posts

Historical OCGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.551.641.181.356,502,620-0.28-18.06%
1 Month1.832.081.181.6410,239,111-0.56-30.60%
3 Months0.5722.1050.4951.329,622,2150.698122.03%
6 Months0.4012.1050.3451.135,815,6660.869216.71%
1 Year0.802.1050.3450.84915145,548,0980.4758.75%
3 Years9.6817.650.3456.7813,772,837-8.41-86.88%
5 Years3.2418.770.175.4517,804,180-1.97-60.80%

Ocugen Description

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Your Recent History

Delayed Upgrade Clock